Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

CCL3 Enhances Antitumor Immune Priming in the Lymph Node via IFNγ with Dependency on Natural Killer Cells.

Allen F, Rauhe P, Askew D, Tong AA, Nthale J, Eid S, Myers JT, Tong C, Huang AY.

Front Immunol. 2017 Oct 23;8:1390. doi: 10.3389/fimmu.2017.01390. eCollection 2017.

2.

CCL3 augments tumor rejection and enhances CD8+ T cell infiltration through NK and CD103+ dendritic cell recruitment via IFNγ.

Allen F, Bobanga ID, Rauhe P, Barkauskas D, Teich N, Tong C, Myers J, Huang AY.

Oncoimmunology. 2017 Nov 20;7(3):e1393598. doi: 10.1080/2162402X.2017.1393598. eCollection 2018.

PMID:
29399390
3.

Tumor-induced suppression of antitumor reactivity and depression of TCRzeta expression in tumor-draining lymph node lymphocytes: possible relationship to the Th2 pathway.

Fu EJ, Arca MJ, Hain JM, Krinock R, Rado J, Cameron MJ, Chang AE, Sondak VK.

J Immunother. 1997 Mar;20(2):111-22.

PMID:
9087383
4.

Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response.

Thomas SN, Vokali E, Lund AW, Hubbell JA, Swartz MA.

Biomaterials. 2014 Jan;35(2):814-24. doi: 10.1016/j.biomaterials.2013.10.003. Epub 2013 Oct 18.

5.

Profile of regulatory T cells and interferon γ secretion in the tumor-draining lymph node from mouse Hepa1-6 cells.

Wang LK, Kuang M, Hua YP, He Q, Chen B, Wang Y, Peng BG.

J Surg Res. 2013 Aug;183(2):900-6. doi: 10.1016/j.jss.2013.02.001. Epub 2013 Feb 24.

PMID:
23481561
6.

Enhancing efficacy of anticancer vaccines by targeted delivery to tumor-draining lymph nodes.

Jeanbart L, Ballester M, de Titta A, Corthésy P, Romero P, Hubbell JA, Swartz MA.

Cancer Immunol Res. 2014 May;2(5):436-47. doi: 10.1158/2326-6066.CIR-14-0019-T. Epub 2014 Feb 11.

7.

Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.

Kuhn S, Hyde EJ, Yang J, Rich FJ, Harper JL, Kirman JR, Ronchese F.

J Immunol. 2013 Aug 15;191(4):1984-92. doi: 10.4049/jimmunol.1301135. Epub 2013 Jul 15.

8.

TLR7 ligand augments GM-CSF-initiated antitumor immunity through activation of plasmacytoid dendritic cells.

Narusawa M, Inoue H, Sakamoto C, Matsumura Y, Takahashi A, Inoue T, Watanabe A, Miyamoto S, Miura Y, Hijikata Y, Tanaka Y, Inoue M, Takayama K, Okazaki T, Hasegawa M, Nakanishi Y, Tani K.

Cancer Immunol Res. 2014 Jun;2(6):568-80. doi: 10.1158/2326-6066.CIR-13-0143. Epub 2014 Apr 10.

9.

Simultaneous targeting of CD3 on T cells and CD40 on B or dendritic cells augments the antitumor reactivity of tumor-primed lymph node cells.

Li Q, Grover AC, Donald EJ, Carr A, Yu J, Whitfield J, Nelson M, Takeshita N, Chang AE.

J Immunol. 2005 Aug 1;175(3):1424-32.

10.

Synergistic effects of IL-12 and IL-18 in skewing tumor-reactive T-cell responses towards a type 1 pattern.

Li Q, Carr AL, Donald EJ, Skitzki JJ, Okuyama R, Stoolman LM, Chang AE.

Cancer Res. 2005 Feb 1;65(3):1063-70.

11.

Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs.

Nakamura M, Iwahashi M, Nakamori M, Ueda K, Ojima T, Naka T, Ishida K, Yamaue H.

Oncology. 2005;68(2-3):163-70. Epub 2005 Jul 4.

PMID:
16006753
12.

NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells.

Shibolet O, Alper R, Zlotogarov L, Thalenfeld B, Engelhardt D, Rabbani E, Ilan Y.

Int J Cancer. 2003 Aug 20;106(2):236-43.

13.

Flagellin enhances NK cell proliferation and activation directly and through dendritic cell-NK cell interactions.

Tsujimoto H, Uchida T, Efron PA, Scumpia PO, Verma A, Matsumoto T, Tschoeke SK, Ungaro RF, Ono S, Seki S, Clare-Salzler MJ, Baker HV, Mochizuki H, Ramphal R, Moldawer LL.

J Leukoc Biol. 2005 Oct;78(4):888-97. Epub 2005 Jul 20.

PMID:
16033815
14.

Disrupted lymph node and splenic stroma in mice with induced inflammatory melanomas is associated with impaired recruitment of T and dendritic cells.

Soudja SM, Henri S, Mello M, Chasson L, Mas A, Wehbe M, Auphan-Anezin N, Leserman L, Van den Eynde B, Schmitt-Verhulst AM.

PLoS One. 2011;6(7):e22639. doi: 10.1371/journal.pone.0022639. Epub 2011 Jul 21.

15.

[Enhancing antitumor activity of tumor-draining lymph node cells by autologous dendritic cells].

Peng Z, Li R, Li L, Zhang L, Jin T.

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2004 Sep;20(5):595-7. Chinese.

PMID:
15367357
16.

Antitumor activity of T cells generated from lymph nodes draining the SEA-expressing murine B16 melanoma and secondarily activated with dendritic cells.

Yu J, Tian R, Xiu B, Yan J, Jia R, Zhang L, Chang AE, Song H, Li Q.

Int J Biol Sci. 2009;5(2):135-46. Epub 2009 Jan 20.

17.

TRAIL/DR5 plays a critical role in NK cell-mediated negative regulation of dendritic cell cross-priming of T cells.

Iyori M, Zhang T, Pantel H, Gagne BA, Sentman CL.

J Immunol. 2011 Sep 15;187(6):3087-95. doi: 10.4049/jimmunol.1003879. Epub 2011 Aug 10.

18.

CD40ligand-expressing dendritic cells induce regression of hepatocellular carcinoma by activating innate and acquired immunity in vivo.

Gonzalez-Carmona MA, Lukacs-Kornek V, Timmerman A, Shabani S, Kornek M, Vogt A, Yildiz Y, Sievers E, Schmidt-Wolf IG, Caselmann WH, Sauerbruch T, Schmitz V.

Hepatology. 2008 Jul;48(1):157-68. doi: 10.1002/hep.22296.

PMID:
18537185
19.

Enhanced Antitumor Immunity Elicited by Dendritic Cell Vaccines Is a Result of Their Ability to Engage Both CTL and IFNγ-producing NK Cells.

Karimi K, Boudreau JE, Fraser K, Liu H, Delanghe J, Gauldie J, Xing Z, Bramson JL, Wan Y.

Mol Ther. 2008 Feb;16(2):411-418. doi: 10.1038/sj.mt.6300347. Epub 2016 Dec 7.

PMID:
28178541
20.

The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity.

Prins RM, Craft N, Bruhn KW, Khan-Farooqi H, Koya RC, Stripecke R, Miller JF, Liau LM.

J Immunol. 2006 Jan 1;176(1):157-64.

Supplemental Content

Support Center